Osteodystrophy is a bone disorder caused by chronic renal failure and is commonly found in patients undergoing dialysis therapy. It includes osteomalacia, osteoporosis, osteosclerosis, and osteitis fibrosa, each caused by hormonal imbalances impacting calcium balance and bone metabolism. Treatment depends on the combination of bone disorders, with calcium and vitamin D supplements used for osteoporosis and osteitis fibrosa, and reducing toxins to prevent osteosclerosis.
Osteodystrophy is a disorder in which a person suffers from a variety of bone disorders. Typical disorders associated with osteodystrophy include osteomalacia, osteoporosis, osteosclerosis, and osteitis fibrosa. Osteodystrophy is typically caused by chronic renal failure, also known as kidney disease. It can also occur in individuals born with a malfunctioning kidney.
Osteiodystrophy is most commonly found in patients undergoing dialysis therapy. Since kidney disease can cause death if not treated with dialysis therapy, the person has no choice but to risk the possibility of developing osteodystrophy. Due to its close association with renal failure and dialysis, osteodystrophy is also commonly referred to as renal osteodystrophy or chronic hemodialysis.
Each of the diseases associated with osteodystrophy can be quite serious. Osteomalacia causes bones to soften when the amount of calcium they contain decreases. With osteoporosis, a patient’s bones lose mass and become porous and brittle. Osteosclerosis, on the other hand, is characterized by hardened bones. In patients with osteitis fibrosa, calcium in the bones is replaced with scar-type tissue.
Each of the bone disorders associated with osteodystrophy is caused by a hormonal imbalance, which has a major impact on calcium balance and bone metabolism. Additionally, osteomalacia is often the first of these disorders to form due to aluminum deposits that form in the bone during dialysis, which cannot be adequately removed due to impaired kidney function. Treatment of osteodystrophy depends on the combination of bone disorders that the patient has developed. If the patient has osteomalacia, the treatment may be to reduce the amount of aluminum in the dialysis treatment and occasionally remove the aluminum from the patient’s body with the help of special drugs.
Patients who have developed osteoporosis and osteitis fibrosa are usually treated with calcium and vitamin D supplements. Osteosclerosis, on the other hand, can be prevented by keeping toxins, such as uremia, from accumulating in the patient’s body. This can be a difficult task, as the kidneys are not functioning normally and, therefore, cannot assist in the removal process.
Protect your devices with Threat Protection by NordVPN
